N
LRMR icon

Nuveen’s Larimar Therapeutics LRMR Stock Holding History

Nuveen’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.04M Buy
674,915
+569,733
+542% +$2.28M ﹤0.01% 2101
2025
Q4 		$401K Hold
105,182
– – ﹤0.01% 2962
2025
Q3 		$340K Sell
105,182
-121,820
-54% -$457K ﹤0.01% 3025
2025
Q2 		$656K Buy
227,002
+52,214
+30% +$121K ﹤0.01% 2787
2025
Q1 		$376K Hold
174,788
– – ﹤0.01% 2984
2024
Q4 		$676K Hold
174,788
– – ﹤0.01% 2877
2024
Q3 		$1.14M Sell
174,788
-36,040
-17% -$290K ﹤0.01% 2696
2024
Q2 		$1.53M Buy
210,828
+104,598
+98% +$801K ﹤0.01% 2510
2024
Q1 		$806K Buy
106,230
+67,738
+176% +$528K ﹤0.01% 2783
2023
Q4 		$175K Buy
38,492
+2,837
+8% +$9.57K ﹤0.01% 3235
2023
Q3 		$141K Hold
35,655
– – ﹤0.01% 3088
2023
Q2 		$112K Buy
+35,655
New +$145K ﹤0.01% 3151

Other funds holding LRMR

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Nuveen's LRMR Position: Q1 2026 in Review

Nuveen increased its Larimar Therapeutics (LRMR) stake by 542% in Q1 2026, buying an estimated $2.28M and bringing the position to 674,915 shares worth $3.04M. The position accounts for ﹤0.01% of the portfolio, ranked #2101.

Nuveen first reported a position in LRMR in Q2 2023 and has held it in 12 quarters since. 162 funds tracked by Wall St. Rank hold LRMR as of Q1 2026.

  • Nuveen held 674,915 shares of Larimar Therapeutics worth $3.04M as of Q1 2026.
  • Nuveen bought 569,733 Larimar Therapeutics shares in Q1 2026, an estimated $2.28M.
  • Larimar Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #2101 holding.
  • Nuveen first reported a position in Larimar Therapeutics in Q2 2023 and has held it in 12 quarters since.
  • 162 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.